INTRODUCTION
============

Chronic obstructive pulmonary disease(COPD) represents one of the highest economic and social burdens among chronic diseases ^\[[@b1-jtim-2015-0029]\]^. Delayed diagnosis of COPD affects prevalence and mortality reports ^\[[@b1-jtim-2015-0029],[@b2-jtim-2015-0029]\]^, and there were reports from the World Health Organization (WHO) expecting it to become the third cause of death in 2020. Co-morbidities of COPD play a role in prognosis and mortality, especially cardiac co-morbidity, which is often underestimated ^\[[@b1-jtim-2015-0029]\]^. Previous studies mentioned that hypertension, heart failure and ischemic heart diseases, anemia and osteoporosis, anxiety and depression, cachexia, and myopathy are noticed more frequently in COPD patients than in the general population ^\[[@b1-jtim-2015-0029],[@b3-jtim-2015-0029],[@b4-jtim-2015-0029],[@b5-jtim-2015-0029]\]^.

Tobacco smoking is considered as a major risk factor for cardiac diseases and COPD. However, in COPD, oxidative stress and the consequent release of humeral inflammatory mediators, not only in the lungs but also in the systemic circulation, play an additional role in these co-morbidities ^\[[@b6-jtim-2015-0029],[@b7-jtim-2015-0029]\]^. In this article, we present our study on co-morbidities and COPD.

MATERIALS AND METHODS
=====================

Patients with COPD in 2012, admitted to Lattakia University Hospital, were assessed for co-morbidities. All patients gave their consent to participate in this study.

COPD diagnoses were confirmed by spirometry according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) \<70% after 4 puffs of bronchodilator\]. The test was performed in respect of the ATS/ERS guidelines ^\[[@b8-jtim-2015-0029],[@b9-jtim-2015-0029]\]^. Accordingly the patients were classified depending on the FEV1 value into four stages according to GOLD: mild COPD (FEV1 ≥ 80% predicted), moderate COPD (FEV1 50--80% predicted), severe COPD (FEV1 30--50% predicted), and very severe COPD (FEV1 \< 30% predicted) ^\[[@b1-jtim-2015-0029]\]^. Blood gases were also measured.

A questionnaire was distributed to all patients screening for cough, sputum, and dyspnea according to Modified Medical Research Council Questionnaire (mMRC scale), ischemic heart disease, smoking history, and co-morbidities.

Our clinical investigation consisted of measuring blood pressure (considered high if \>14 for systolic pressure and \>9 for diastolic pressure) by electrocardiograph (ECG), and Cardiac Echo-Doppler. The blood investigation consisted of hemoglobin (Hb), creatinine, fasting blood glucose, and C-reactive protein (CRP). We considered anemia when Hg \< 12 g/dL and renal failure when creatinine \> 1.2 mg/dL. We also measured bone mineral density for osteoporosis. When lung cancer was suspected, bronchoscopy, fine needle biopsy, or if necessary open lung biopsy was performed to confirm diagnosis.

Analysis for associations was performed by Stata Logiciel. Chi square or Fisher test was performed for association. *P* was considered significant when \<0.05.

RESULTS
=======

Our results are presented in tables. The main characteristics of our population are presented in [Table 1](#t1-jtim-2015-0029){ref-type="table"}: 72 of our 99 patients are males; 67% smokers with mean quantity smoked 57 **±** 33.77 packs/year. The patient age was 63.17 **±** 10.74 years, mean FEV1 and SD 0.52 **±** 16 L/sec. Only 4% were stage I COPD by GOLD (FEV1≥ 80%), suggesting a high level of severity and probably reflecting the delay in diagnosis; especially and surprisingly, 38% have respiratory failure (PaO2 \< 60 mmgh).

CRP = 52.34 mg/L±49 (the normal is 6), which is very high reflecting the systemic inflammation.

Co-morbidities in the study population are presented in [Table 2](#t2-jtim-2015-0029){ref-type="table"}. The most prevalent co-morbidities were cardiac disorders, with heart failure in 47%, ischemic heart diseases in 37.37%, pulmonary hypertension in 47.47%, and hypertension in 61% of all subjects. Other co-morbidities were less frequent.

[Table 3](#t3-jtim-2015-0029){ref-type="table"} represents the number of co-morbidities according to the GOLD stage (based on FEV1% predicted after bronchodilators): the frequency of diabetes, heart failure, and pulmonary hypertension is significantly associated with GOLD stage of FEV1 (*P* = 0.01 for diabetes, 0.003 for heart failure, and 0.0001 for pulmonary hypertension, respectively).

As shown by [Table 2](#t2-jtim-2015-0029){ref-type="table"}, over 88% of patients have more than one condition of co-morbidities. The number of co-morbidities \>3 is significantly associated with the GOLD degree of severity based on FEV1 value ([Table 3](#t3-jtim-2015-0029){ref-type="table"}; *P* = 0.0001).

DISCUSSION
==========

COPD is characterized by persistent inflammation that is usually progressive and associated with enhanced chronic inflammatory response in airway and the lung tissues in response to noxious particles and gases (cigarette smoke). Co-morbidities contribute to the overall severity of symptoms in individual patients. The chronic and progressive airway limitation characteristic of COPD is caused by lung inflammation leading to small airway fibrosis, air trapping, and the resulting breathlessness ^\[[@b1-jtim-2015-0029]\]^.

Bearing in mind the suffering of Syrians currently, it is our duty to improve the clinical services in Syria, including gaining a better understanding of the integrated management of co-morbidities in all COPD patients, especially cardiac ones, and vice versa to screen for nondiagnosed COPD in cardiac patients exposed to risk factors (smokers). We believe that this is the first report emerging from Syria concerning COPD and its co-morbidities.

Our main results are the significant association of COPD with heart failure and pulmonary hypertension; hypertension is present in 61%.

Co-morbidities could be explained by systemic inflammation. The chronic inflammation in the respiratory tract of COPD patients is an abnormal exaggerated response to noxious particles and gases resulting from severe exposure to irritants like cigarette smoke. Oxidative stress plays a major role, and oxidants are released from inflammatory cells such as macrophages and neutrophils; these are present not only in the lungs, but also in systemic circulation, which could play a big role in the occurrence of co-morbidities ^\[[@b1-jtim-2015-0029],[@b6-jtim-2015-0029],[@b7-jtim-2015-0029]\]^.

Although risk factors are the same for these co-morbidities (smoking), these conditions are more prevalent in COPD patients than in the general population ^\[[@b1-jtim-2015-0029],[@b3-jtim-2015-0029],[@b4-jtim-2015-0029],[@b5-jtim-2015-0029]\]^.

In a study from Spain, Almagro *et al.* highlighted in a multicenter study in 398 COPD patients, 11% females, and mean FEV1 \< 43% that, hypertension is present in 55% and 61% in our series. Twenty seven percent have diabetes and 25.25% in our study. Forty seven percent in our study have heart failure and 27% in their study; 33% in their study have anemia and 44.9% in our study ^\[[@b3-jtim-2015-0029]\]^.

An American series studied 1003 patients in 2011 ^\[[@b4-jtim-2015-0029]\]^, and they found the prevalent co-morbidities, including hypertension (55%), depression (37%), and osteoporosis (28%). However, we did not determine depression in our study.

In a multicenter study published by the International Primary care Respiratory Group (IPCRG) in 2008 ^\[[@b5-jtim-2015-0029]\]^, the number of co-morbid conditions was 3.2 for patients with COPD ^\[[@b5-jtim-2015-0029]\]^. In our results, 88% of patients have more than one co-morbidity, with more than three conditions associated with the GOLD degree of severity ([Tables 2](#t2-jtim-2015-0029){ref-type="table"} and [3](#t3-jtim-2015-0029){ref-type="table"}).

Comparing our results to the above-mentioned studies, cardiac co-morbidities and anemia are more prevalent in our population. Further research is needed to explain this issue.

We also notice that the number of co-morbidities is positively associated with the GOLD stage of FEV1, which leads us to recommend spirometry in every person having risk factors (e.g., smoking) and complaining of chronic cough, sputum, or dyspnea. Early diagnosis is our ultimate tool to improve COPD care and prevent co-morbidities ^\[[@b1-jtim-2015-0029],[@b2-jtim-2015-0029],[@b10-jtim-2015-0029]\]^.

We should assess co-morbidities in all COPD patients and vice versa especially for cardiac co-morbidities. This is especially when we know that treating co-morbidities improves life expectancy ^\[[@b1-jtim-2015-0029],[@b11-jtim-2015-0029]\]^.

As regards the limitations of our study, the number of patients in each category is limited (e.g., only 4 are stage IGOLD). Also we did not assess all co-morbidities (e.g., anxiety and depression, cachexia). For future research, we should first concentrate on how to implement co-morbidity assessment in all COPD patients and in all settings, especially in primary care. Second, we must work for early diagnosis, because our results showed higher co-morbidities in advanced stages of COPD.

In conclusion, although irreversible airflow limitation is the main characteristic of COPD, COPD is also a systemic disease causing co-morbidities. Screening all COPD patients for cardiac diseases, hypertension, osteoporosis, and other co-morbidities, and integrated management should be part of our daily practice ^\[[@b11-jtim-2015-0029]\]^.
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###### 

Characteristics of our population of COPD patients (*n* = 99)

  --------------------------------------------------------------------- --------------------------------------------
  Age (mean and SD)                                                     63.17 ± 10.74 years
  Gender                                                                72% male
  FEV1 (mean and SD)                                                    0.52 L/s ±16
  FEV1 GOLD Stage[\*](#tfn1-jtim-2015-0029){ref-type="table-fn"}        I (4%), II (42%), III (39%), IV (24%)
  FEV1/FVC after bronchodilators (mean and SD)                          0.59 ± 0.10
  Smokers                                                               67%
  Pack/year (mean and SD)                                               57 ± 33.77
  Cough                                                                 72%
  Dyspnea mMRC scale[\*\*](#tfn2-jtim-2015-0029){ref-type="table-fn"}   0 (6%), 1 (22%), 2 (33%), 3 (24%), 4 (14%)
  Respiratory failure (PO2 \< 60 mmHg)                                  38%
  CRP (mean and SD)                                                     52.34 mg/L ± 49
  Hb                                                                    12.42 ± 2.11 g/dL
  Renal failure (*n*)                                                   13 (13.13%)
  Glycemia                                                              115 ± 30 mg/dL
  --------------------------------------------------------------------- --------------------------------------------

Degree of airflow limitation according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD);

Modified Medical Research Council (mMRC) Questionnaire for assessing the severity of breathlessness

###### 

Percentage of co-morbidities in COPD patients (*n* = 99)

  ------------------------- --------
  Hypertension              61.62%
  Diabetes                  25.25%
  Heart failure             47%
  Ischemic heart diseases   37.37%
  Atrial fibrillation       13.13%
  Anemia                    44%
  Pulmonary hypertension    47.47%
  Cancer                    20%
  Osteoporosis              25%
  ------------------------- --------

Note: 88% have more than one co-morbidities. COPD: chronic obstructive pulmonary disease.

###### 

GOLD stage and co-morbidities

  Co-morbidities                 GOLD stage   *P* value                        
  ------------------------------ ------------ ----------- ---------- --------- --------
  Hypertension                   75%          47%         69%        75%       0.1
  Diabetes                       0%           11.9%       31%        46%       0.01
  Heart failure                  25%          31%         52%        75%       0.003
  Ischemic heart diseases        25           38%         28%        50%       0.39
  Pulmonary hypertension         0%           26%         55%        83%       0.0001
  Cancer                         1%           14%         18%        20%       0.15
  Hospitalization                25%          33%         62%        83%       0.001
  Number of Co-morbidities \>3   1 (25%)      16 (38%)    27 (93%)   23(95%)   0.0001

GOLD: Global Initiative for Chronic Obstructive Lung Disease.
